Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes
Status:
Terminated
Trial end date:
2021-01-13
Target enrollment:
Participant gender:
Summary
Opioid analgesics are the most common postoperative pain medications used among dentists in
the United States.Although these medications are highly effective in the postoperative dental
pain management, not all patients optimally benefit from this therapy. Many suffer adverse
consequences such as nausea, emesis, and psychomotor impairment, and there is a high
prevalence of opioid prescription misuse among substance abusers within the dental patient
population.
The use of non-opioid analgesics including ibuprofen and acetaminophen in the management of
postoperative dental pain has demonstrated equivalent or superior analgesic effects compared
to opioid analgesic therapies, typically with significantly less adverse effects.However,
despite these results, dentists have encountered a high variability in the success of
non-opioid analgesic responses among the postoperative dental pain population.Thus, new
strategies for earlier recognition of analgesic responses for pain medications is fundamental
in the field of dentistry. Therefore, this study will evaluate the clinical utility of
pharmacogenomic testing in acute postoperative dental pain management among healthy adults
who undergo extraction of impacted mandibular third molar.